Benzinga
04 May 2026, 17:46 UTC · 20w ago
Verdict
Headline takes no side. We score TWST +0.20 across five claims — slightly bullish.
+0.20slightly bullish
More positive than 48% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Twist Bioscience raised its fiscal 2026 sales guidance to $442 million–$447 million and provided Q3 guidance above consensus.
More positive than 92% of claims this week
The company reported an adjusted loss of 59 cents per share, missing the consensus estimate of a 48 cent loss.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More negative than 85% of claims this week
Quarterly sales reached $110.72 million, beating both the consensus of $107.66 million and management's own guidance.
More positive than 62% of claims this week
Management expects to achieve adjusted EBITDA breakeven in the fourth quarter of fiscal 2026.
More positive than 62% of claims this week
Twist Bioscience reached a settlement in principle for a securities class action costing approximately $17.1 million.
More negative than 66% of claims this week
Which stocks this story touches
More positive than 48% of ticker scores this week
The company beat revenue expectations and raised future guidance, though it missed earnings per share and saw a widening loss.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+169.9%
Price agrees with the score
$163.00 vs $60.40 close before publication (May 1) · not market-adjusted
TWST chart →